



A Longitudinal Examination of Intersectional Stigma, Antiretroviral Adherence, and Viral Load

Kristi L. Stringer, PhD

Adherence 2023 • June 11-13 • Puerto Rico



Financial/Funding Disclosures

- National Institute on Drug Abuse
 - R25DA037190; R03DA052180;
- National Institute of Mental Health
 - K01MH125724; R01MH131177; P30-MH-116867
- National Heart, Lung, and Blood Institute
 - U01-HL146241; U01-HL146242; U01-HL146192
- National Center for Advancing Translational Sciences
 - UL1-TR000004; UL1-TR003098; UL1-TR001881
- Intramural Research, National Institute of Allergy and Infectious Diseases
 - P30-AI-050409; P30-AI-073961; P30-AI-050410; P30-AI-027767



Stigma Is

A degrading and debasing attitude of the society that discredits a person or group based on an aspect of their social identity, medical diagnosis, or participation in an undesirable behavior.

Experienced/Enacted Stigma

- overt acts of discrimination, such as exclusion, acts of physical or emotional abuse, and subtle negative treatment; acts may be within or beyond the purview of the law.




Intersectional Stigma

- Synergistic, mutually constitutive associations between different social identities and inequities
- The intersection of HIV- and other stigmas can create unique intersectional profiles of social exclusion and marginalization, which may exacerbate social and health inequalities.






Conceptual Framework for HIV-Related Stigma, Engagement in Care, and Health Outcomes



Turan et al 2017



Rueda et al 2016; Armoon et al 2022



Objectives: To explore the associations between intersectional poverty, HIV, sex, and racial stigma, adherence to antiretroviral therapy (ART), and viral suppression among women with HIV (WHIV).

Design: We examined intersectional stigmas, self-report ART adherence, and viral suppression using cross-sectional data.

Methods: Participants were WHIV ($N=459$) in the Women's Adherence and Visit Engagement, a Women's Interagency HIV Study substudy. We used Multidimensional Latent Class Item Response Theory and Bayesian models to analyze intersectional stigmas and viral load adjusting for sociodemographic and clinical covariates.

Results: We identified five intersectional stigma-based latent classes. The likelihood of viral suppression was approximately 90% lower among WHIV who experienced higher levels of poverty, sex, and racial stigma or higher levels of all intersectional stigmas compared with WHIV who reported lower experiences of intersectional stigmas. ART adherence accounted for but did not fully mediate some of the associations between latent intersectional stigma classes and viral load.

Conclusion: The negative impact of intersectional stigmas on viral suppression is likely mediated, but not fully explained, by reduced ART adherence. We discuss the research and clinical implications of our findings.

Study Aim

To longitudinally explore the effects of intersecting HIV, race, gender, and poverty-related experienced stigma on ART adherence and viral load among women with HIV



Participants

- Women with HIV (WHIV) in the Women's Adherence and Visit Engagement (WAVE)
 - A sub-study of the Women's Interagency HIV Study (WIHS)
 - Four WIHS sites to represent different parts of the country:
 - Birmingham, Alabama
 - Jackson, Mississippi
 - Atlanta, Georgia
 - San Francisco, California
 - The collection of the data used in this study took place between (April) 2016 and (October) 2020.
 - 4 Annual Time Points (Ts)



Methods

- Identify Intersectional Classes
 - Multidimensional Latent Transition Item Response Analysis
- Explore The Longitudinal Relationship Of Intersectional Stigma And Adherence Over Time
 - Latent Markov Model path-analysis
 - Logistic and multinomial regression
 - Pairwise comparisons using Wald Tests



Multidimensional Latent Transition Item Response Theory - MLTIRT

- Integrates item response theory (IRT), latent class/Transition analysis (LCTA)
- Identifies homogenous subgroups of individuals with similar (a) levels of and (b) relationships between intersectional stigmas
- Accounts for measurement error and item contribution to measuring underlying constructs/traits (i.e., intersectional stigmas)
- Accounts for dynamic, time-varying experiences of intersectional stigmas



Sample Characteristics

	Overall <i>N</i> = 459
Age (mean (SD))	49.06 (9.45)
White, <i>n</i> (%)	68 (14.8)
Non-Latina, <i>n</i> (%)	426 (92.8)
Highest level of education, <i>n</i> (%)	
1. <High school/GED	129 (28.6)
2. High school/GED	141 (31.3)
3. Some college/associate	142 (31.5)
4. College and above	39 (8.6)
Highest level of education, median (IQ)	2 [1, 3]
Average yearly household income, <i>n</i> (%)	
1. \$12 000 or less	250 (57.1)
2. \$12 001–24 000	99 (22.6)
3. \$24 001–36 000	42 (9.6)
4. \$36 001 or more	47 (10.7)
Average yearly household income, median [IQ]	1 [1, 2]
Viral load suppression (<20 copies/ml), <i>n</i> (%)	305 (67.6)
≥ 95% ART adherence over past 6 months, <i>n</i> (%)	350 (82.2)
Time since ART initiation, months (mean (SD))	103.74 (71.58)
Experienced intersectional stigmas raw scores (mean (SD))	
Poverty	6.05 (4.24)
HIV	16.44 (8.75)
Gender	9.07 (7.15)
Racial	2.21 (2.99)

ART, antiretroviral therapy; IQ, interquartile range; SD, standard deviation.



Intersectional Stigma Classes





Fig. 1. Experienced poverty-, HIV-, sex-, and racial-stigma by class. Standardized levels of experienced stigma (latent trait scores) by latent class. The overall sample mean of each experienced stigma (latent trait) is 0 because latent trait scores are standardized variables. For each class, we show experienced stigma levels higher/lower than the sample mean as indicated by standardized scores above/below 0.




MLTIRT - Latent transition

- Dynamic process
 - Participants can transition to other classes over time based on their experiences of intersectional stigma.



Intersectional stigma transition probabilities

#ADHERENCE2023



		T				
		Class 1	Class 2	Class 3	Class 4	Class 5
T-1	Class 1	0.631	0.232	0.097	0.040	0.001
	Class 2	0.133	0.681	0.083	0.095	0.008
	Class 3	0.054	0.221	0.560	0.107	0.059
	Class 4	0.056	0.161	0.080	0.548	0.155
	Class 5	0.014	0.066	0.122	0.255	0.543



Adherence and VL transition probabilities


ART adherence T			
ART adherence T-1	<80%	80-90%	≥90%
<80%	0.5706	0.2091	0.2203
80-90%	0.2196	0.3588	0.4216
≥90%	0.0919	0.1715	0.7366

Viral Load T		
Viral Load T-1	Undetectable	Detectable
Undetectable	0.7734	0.2266
Detectable	0.4158	0.5842

Intersectional Experienced Stigmas and Viral Load

(Ref Group Class 1)

#ADHERENCE2023



Initial state

Predictor	OR	CI	sig
Class 1 Ref.			
Class 2	1.437	(0.68, 3.036)	0.3400
Class 3	2.608	(1.339, 5.079)	0.0048
Class 4	2.025	(0.989, 4.146)	0.0540
Class 5	1.675	(0.796, 3.526)	0.1700

IV = Independent variable; OR = odds ratios; CIs = 95% confidence interval; sig= p-value; model adjusted for covariates.

Over time


Predictor	OR	CI	sig
Class 1 Ref.			
Class 2	0.774	(0.514, 1.164)	0.220
Class 3	1.349	(0.9, 2.022)	0.150
Class 4	0.983	(0.634, 1.525)	0.940
Class 5	1.763	(1.1, 2.826)	0.019

IV = Independent variable; OR = odds ratios; CIs = 95% confidence interval; sig= p-value; model adjusted for covariates.

Intersectional Experienced Stigmas & Viral Load

(Ref Group Class 2)

#ADHERENCE2023



Initial state

Predictor	OR	CI	sig
Class 2			
Class 3	1.995	(1, 3.98)	0.05
Class 4	1.199	(0.572, 2.513)	0.63
Class 5	1.140	(0.529, 2.456)	0.74

IV = Independent variable; OR = odds ratios; CIs = 95% confidence interval; sig= p-value; model adjusted for covariates.

Over time


Predictor	OR	CI	sig
Class 2			
Class 3	1.562	(1.074, 2.271)	0.02000
Class 4	1.245	(0.832, 1.864)	0.29000
Class 5	2.108	(1.369, 3.247)	0.00072

IV = Independent variable; OR = odds ratios; CIs = 95% confidence interval; sig= p-value; model adjusted for covariates.

Initial state

Predictor	DV	OR	CI	sig
Class 1 (Ref)	≥90 % (Ref)			
Class 2	80-90 %	1.212	(0.523, 2.806)	0.65
Class 2	<80 %	3.018	(1.056, 8.628)	0.039
Class 1 (Ref)	≥90 % (Ref)			
Class 3	80-90 %	2.634	(1.249, 5.556)	0.011
Class 3	<80 %	7.451	(2.82, 19.685)	0.00005
Class 1 (Ref)	≥90 % (Ref)			
Class 4	80-90 %	1.558	(0.677, 3.583)	0.300
Class 4	<80 %	3.742	(1.342, 10.434)	0.012
Class 1 (Ref)	≥90 % (Ref)			
Class 5	80-90 %	1.042	(0.402, 2.705)	0.930
Class 5	<80 %	8.226	(3.032, 22.321)	0.00004

#ADHERENCE2023




Intersectional stigma and Adherence

Class 1 Ref Group

Over Time

Predictor	DV	OR	CI	sig
Class 1 (Ref)	≥90 % (Ref)			
Class 2	80-90%	0.978 (0.597, 1.604)		0.930
Class 2	<80%	1.01 (0.591, 1.761)		0.940
Class 1 (Ref)	≥90 % (Ref)			
Class 3	80-90%	1.799 (1.085, 2.983)		0.023
Class 3	<80%	1.694 (0.966, 2.971)		0.066
Class 1 (Ref)	≥90 % (Ref)			
Class 4	80-90%	1.213 (0.716, 2.054)		0.470
Class 4	<80%	1.242 (0.709, 2.177)		0.450
Class 1 (Ref)	≥90 % (Ref)			
Class 5	80-90%	1.318 (0.712, 2.44)		0.380
Class 5	<80%	1.714 (0.948, 3.098)		0.074

#ADHERENCE2023



Intersectional stigma and Adherence

Class 1 Ref Group



Discussion

- 5 Different combinations of experienced intersectional stigmas are associated with viral load and adherence
- Groups were differently associated with ART adherence and detectable viral load
- Negative impact of HIV stigma on HIV treatment outcomes could be intensified when individuals also face other forms of stigma simultaneously.



References

- **Turan, B et al.** “Framing Mechanisms Linking HIV-Related Stigma, Adherence to Treatment, and Health Outcomes.” *American Journal of Public Health* 107, no. 6 (June 2017): 863–69. <https://doi.org/10.2105/AJPH.2017.303744>.
- **Rueda, Sergio, et al.** "Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses." *BMJ open* 6.7 (2016): e011453.
- **Armoon, Bahram, et al.** "HIV related stigma associated with social support, alcohol use disorders, depression, anxiety, and suicidal ideation among people living with HIV: a systematic review and meta-analysis." *International Journal of Mental Health Systems* 16.1 (2022): 1-17.
- **Turan, J. M. et al.** “Challenges and opportunities in examining and addressing intersectional stigma and health.” *BMC medicine*, 17(1), (2019): 7.
- **Norcini Pala, A et al.** “Intersectional stigmas are associated with lower viral suppression rates and antiretroviral therapy adherence among women living with HIV”. *AIDS*, 36(13) (2022): 1769-1776.
- **Mickelson KD, Williams SL.** “Perceived stigma of poverty and depression: examination of interpersonal and intrapersonal mediators.” *J Soc Clin Psychol*; 27 (2008):903.
- **Berger, BE et al.** “Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale.” *Re Nurs Health*; 24 (2001):518–529.
- **Krieger N et al.** “Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health.” *Soc Sci Med*; 61 (2005):1576–1596.
- **Klonoff EA, Landrine H.** “The schedule of sexist events: a measure of lifetime and recent sexist discrimination in women’s lives”. *Psychol Women Q*; 19 (1995):439–470



Thank you!

Kristi.Stringer@Mtsu.edu

Acknowledgments

WAVE study participants

Andrea Norcini Pala, Janet M. Turan, & Bulent Turan, Robert Cook, Mirjam-Colette Kempf, Deborah Konkle-Parker, Tracey E. Wilson, Phyllis C. Tien, Gina Wingood, Torsten B. Neilands, Mallory O. Johnson, Carmen H. Logie, Elizabeth Topper, & Sheri D. Weiser




A Longitudinal Examination of Intersectional Stigma, Antiretroviral Adherence, and Viral Load

Back Up Slides





Experienced Intersectional Stigma Measures

- Discrimination, unfair treatment, exclusion, and devaluation from others in diverse social contexts in the past 12 months.
 - **Experienced poverty stigma** was assessed using the 4-item subscale of the perceived poverty stigma
 - *Mickelson KD, Williams SL. (2008).*
 - **Experienced HIV stigma** was assessed with the 12-item subscale of the HIV Stigma Scale
 - *Berger BE. Et al (2001).*
 - **Experienced sex stigma** assessment comprised the 13-item scale Schedule of Sexist Events
 - *Klonoff EA, Landrine H. (1995)*
 - **Experienced racial stigma** was assessed using the 10-item experiences of discrimination scale
 - *Krieger N. et al. (2005)*





Transition probability




Initial State

#ADHERENCE2023



IV	DV	OR	CI	sig
Class 2 (Ref)	≥90% (Ref)			
Class 3	80-90%	1.839	(1.177, 2.873)	0.0075
Class 3	<80%	1.660	(0.986, 2.795)	0.0560
Class 2 (Ref)	≥90% (Ref)			
Class 4	80-90%	1.239	(0.773, 1.987)	0.3700
Class 4	<80%	1.217	(0.72, 2.057)	0.4600
Class 2 (Ref)	≥90% (Ref)			
Class 5	80-90%	1.347	(0.765, 2.375)	0.3000
Class 5	<80%	1.679	(0.968, 2.913)	0.0650



Intersectional stigma and Adherence


Class 2 Ref Group₂₆

Over Time

#ADHERENCE2023



Predictor	DV	OR	CI	sig
Class 2 (Ref)	≥90% (Ref)			
Class 3	80-90%	2.174	(1, 4.724)	0.050
Class 3	<80%	2.468	(1.138, 5.355)	0.022
Class 2 (Ref)	≥90% (Ref)			
Class 4	80-90%	1.286	(0.543, 3.044)	0.570
Class 4	<80%	1.240	(0.531, 2.895)	0.620
Class 2 (Ref)	≥90% (Ref)			
Class 5	80-90%	0.860	(0.322, 2.298)	0.760
Class 5	<80%	2.725	(1.205, 6.162)	0.016



Intersectional stigma and Adherence

Class 2 Ref Group₂₇



MLTIRT – Transition probabilities

- At baseline, a person who experienced lower intersectional stigmas over the past 12 months will belong to Class 1
- If the same person experiences some poverty and HIV stigma in the following 12 months will likely belong to Class 2 at the subsequent follow-up

